VICTORIA, BC, Sept. 9, 2020 /CNW/ - IMMUNOPRECISE
ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF)
(FSE:TQB2), a
leader in full-service, therapeutic
antibody discovery and development, today announced
that it will be presenting at the H.C. Wainwright Annual
Global Investment Conference being held virtually on September 14-16, 2020.
Jennifer Bath,
CEO of ImmunoPrecise, will provide an overview of the
Company's business during the live presentation and will be
available to participate in one-on-one meetings with investors who
are registered to attend the conference.
If you are an institutional investor, and would
like to attend the Company's presentation, please click on the
following link (www.hcwevents.com) to register for the conference.
Once your registration is confirmed, you will be prompted to log
into the conference website to request a one-on-one meeting with
the Company.
Event: H.C. Wainwright 22nd Annual
Global Investment Conference (Virtual Conference)
Date: September 14-16, 2020
Presentation Day & Time: September 15,
12:30 PM (EDT)
Location: https://wsw.com/webcast/hcw7/ipa.v/1665422
H.C. Wainwright is a full-service investment bank dedicated to
providing corporate finance, strategic advisory and related
services to public and private companies across multiple sectors
and regions. H.C. Wainwright & Co. also provides research
and sales and trading services to institutional investors.
According to Sagient Research Systems, H.C. Wainwright's
team is ranked as the #1 Placement Agent in terms of aggregate CMPO
(confidentially marketed public offering), RD (registered direct
offering) and PIPE (private investment in public equity) executed
cumulatively since 1998.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with
end-to-end solutions empowering companies to discover and develop
therapies against any disease. The Company's experience and
cutting-edge technologies enable unparalleled support of its
partners in their quest to bring innovative treatments to the
clinic. ImmunoPrecise's full-service capabilities
dramatically reduce the time required for, and the inherent risk
associated with, conventional multi-vendor product development. For
further information, visit www.immunoprecise.com or
contact solutions@immunoprecise.com.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend",
"should" and similar expressions to identify forward-looking
statements. Any such forward-looking statements are based on
assumptions and analyses made by ImmunoPrecise in light
of its experience and its perception of historical trends,
current conditions and expected future developments. However,
whether actual results and developments will conform to
ImmunoPrecise's expectations and predictions is subject to any
number of risks, assumptions and uncertainties. Many factors
could cause ImmunoPrecise's actual results to differ
materially from those expressed or implied by the forward-looking
statements contained in this news release. Such factors include,
among other things, actual revenues and earnings for IPA being
lower than anticipated, and those risks and uncertainties described
in ImmunoPrecise's annual management discussion and
analysis for the previous quarter and audited fiscal
year ended April 30, 2020, which can be accessed
at www.sedar.com. The "forward-looking statements"
contained herein speak only as of the date of this press release
and, unless required by applicable law, ImmunoPrecise undertakes no
obligation to publicly update or revise such information, whether
as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunoprecise-announces-participation-at-the-hc-wainwright-22nd-annual-global-investment-conference-on-september-14-16-2020-virtual-conference-301126952.html
SOURCE ImmunoPrecise Antibodies Ltd.